RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Repare Therapeutics Stock

Repare Therapeutics Equity 2024

Repare Therapeutics Equity

212.08 M USD

Ticker

RPTX

ISIN

US7602731025

WKN

A2P7AV

In 2024, Repare Therapeutics's equity was 212.08 M USD, a -24.12% increase from the 279.5 M USD equity in the previous year.

Repare Therapeutics Aktienanalyse

What does Repare Therapeutics do?

Repare Therapeutics Inc is a biotechnology company specializing in the development of precision medicines for the treatment of cancer. It was founded in 2016 by four leading scientists and is headquartered in Montreal, Canada. The company utilizes an innovative and unique approach called CRISPR-Cas9 to identify and target genetic mutations in cancer cells. The history of Repare Therapeutics Inc stems from a collaboration among renowned cancer researchers. In 2016, the founders, who already had extensive experience in drug development, pooled their resources to create a new generation of cancer therapies. Using the innovative CRISPR-Cas9 system, they were able to specifically identify genetic alterations in cancer cells and significantly reduce tumor burden. Since its inception, the company has formed strong partnerships and successfully raised capital to continue its research and development. Repare Therapeutics has a unique business model focused on developing precision medicine for patients with specific types of cancer. The company combines CRISPR-Cas technology and machine learning to identify genetic mutations in cancer cells and correlate them with an extensive dataset of available clinical studies. This systematic approach allows for faster and more precise identification of suitable target molecules that may serve as potential therapy options for cancer. Repare Therapeutics specializes in quickly and efficiently developing molecules that target these target molecules and advancing them through clinical trials. The company distributes its precision medicines in three different sectors: oncology, therapeutics, and research. The oncology sector specializes in the development of precision medicines for the treatment of cancer. The therapeutics sector offers solutions for the medical care of patients through the development of novel therapies. The research department focuses on developing new precision medicines and advancing innovations in cancer research. Repare Therapeutics offers various products tailored to the needs of cancer patients. The CRISPR-Cas9 technology is being used to advance multiple clinical programs aimed at regulating gene expression in tumor cells and enhancing the effectiveness of cancer therapies. The company's flagship product, RP-3500, is a precision medicine specifically targeted against a gene called KRAS, which plays a crucial role in many types of cancer. The medication has demonstrated strong efficacy in clinical trials and is currently in Phase 1 studies. In summary, Repare Therapeutics Inc is an innovative biotechnology company specializing in the development of precision medicines against cancer. The use of CRISPR-Cas9 technology in combination with machine learning allows for faster identification of suitable target molecules that may serve as potential therapy options for cancer. The company offers various precision medicines that benefit cancer patients. With its numerous research programs and clinical trials, Repare Therapeutics is poised to become a leading player in cancer treatment and research. Repare Therapeutics ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Equity Details

Analyzing Repare Therapeutics's Equity

Repare Therapeutics's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding Repare Therapeutics's equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating Repare Therapeutics's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

Repare Therapeutics's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in Repare Therapeutics’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about Repare Therapeutics stock

What is the equity of Repare Therapeutics this year?

Repare Therapeutics has equity of 212.08 M USD this year.

What was the equity of Repare Therapeutics compared to the previous year?

The equity of Repare Therapeutics has increased/decreased by -24.12% decreased compared to the previous year.

What impact does a high equity have on investors of Repare Therapeutics?

A high equity is advantageous for investors of Repare Therapeutics as it is an indicator of the company's financial stability and its ability to manage risks and challenges.

What impact does low equity have on investors of Repare Therapeutics?

A low equity can be a risk for investors of Repare Therapeutics, as it can put the company in a weaker financial position and impair its ability to manage risks and challenges.

How does an increase in equity of Repare Therapeutics affect the company?

An increase in equity of Repare Therapeutics can strengthen the company's financial position and improve its ability to make investments in the future.

How does a reduction in the equity of Repare Therapeutics affect the company?

A reduction in equity of Repare Therapeutics can affect the financial situation of the company and lead to a higher dependence on debt capital.

What are some factors that influence the equity of Repare Therapeutics?

Some factors that can affect the equity of Repare Therapeutics include profits, dividend payments, capital increases, and acquisitions.

Why is the equity of Repare Therapeutics so important for investors?

The equity of Repare Therapeutics is important for investors as it is an indicator of the financial strength of the company and can be an indication of how well the company is able to fulfill its financial obligations.

What strategic measures can Repare Therapeutics take to change the equity?

To change equity, Repare Therapeutics can take various measures such as increasing profits, conducting capital increases, reducing expenses, and acquiring companies. It is important for the company to perform a thorough review of its financial situation to determine the best strategic actions to modify its equity.

How much dividend does Repare Therapeutics pay?

Over the past 12 months, Repare Therapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Repare Therapeutics is expected to pay a dividend of 0 USD.

What is the dividend yield of Repare Therapeutics?

The current dividend yield of Repare Therapeutics is .

When does Repare Therapeutics pay dividends?

Repare Therapeutics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Repare Therapeutics?

Repare Therapeutics paid dividends every year for the past 0 years.

What is the dividend of Repare Therapeutics?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Repare Therapeutics located?

Repare Therapeutics is assigned to the 'Health' sector.

Wann musste ich die Aktien von Repare Therapeutics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Repare Therapeutics from 8/18/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 8/18/2024.

When did Repare Therapeutics pay the last dividend?

The last dividend was paid out on 8/18/2024.

What was the dividend of Repare Therapeutics in the year 2023?

In the year 2023, Repare Therapeutics distributed 0 USD as dividends.

In which currency does Repare Therapeutics pay out the dividend?

The dividends of Repare Therapeutics are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Repare Therapeutics

Our stock analysis for Repare Therapeutics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Repare Therapeutics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.